Novartis Ag (NVS) Income from Continuing Operations (2009 - 2025)
Novartis Ag recorded quarterly Income from Continuing Operations of 4531000000.0 in Q2 2025, down 34.99% quarter-over-quarter from 6970000000.0 in Q4 2024, and up 17.96% year-over-year from 3841000000.0 in Q2 2024.
Novartis Ag's Income from Continuing Operations history runs 16 years deep, the most recent figure standing at 4531000000.0 for Q2 2025.
- In Q2 2025, Income from Continuing Operations rose 17.96% year-over-year to 4531000000.0; the TTM figure through Jun 2025 stood at 20536000000.0 (up 67.94% YoY), while the FY2025 annual figure was 13967000000.0, up 16.99% from the prior year.
- Income from Continuing Operations came in at 4531000000.0 for Q2 2025 at Novartis Ag, down from 6970000000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 6970000000.0 in Q4 2024 to a low of 514000000.0 in Q1 2021.
- A 5-year average of 3414571428.57 and a median of 4186000000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations soared 164.95% in 2021 and slumped 47.46% in 2023, its largest moves.
- Novartis Ag's Income from Continuing Operations stood at 5956000000.0 in 2021, then fell by 20.9% to 4711000000.0 in 2022, then gained by 10.25% to 5194000000.0 in 2023, then soared by 34.19% to 6970000000.0 in 2024, then sank by 34.99% to 4531000000.0 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 4531000000.0, 6970000000.0, and 3841000000.0 for Q2 2025, Q4 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 7.40 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 5.24 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 697.00 Mn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 2.71 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 2.68 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 4.53 Bn |
| Dec 31, 2024 | 6.97 Bn |
| Jun 30, 2024 | 3.84 Bn |
| Dec 31, 2023 | 5.19 Bn |
| Jun 30, 2023 | 2.67 Bn |
| Mar 31, 2023 | 519.00 Mn |
| Dec 31, 2022 | 4.71 Bn |
| Sep 30, 2022 | 583.00 Mn |
| Jun 30, 2022 | 5.09 Bn |
| Mar 31, 2022 | 595.00 Mn |
| Dec 31, 2021 | 5.96 Bn |
| Sep 30, 2021 | 642.00 Mn |
| Jun 30, 2021 | 5.99 Bn |
| Mar 31, 2021 | 514.00 Mn |
| Dec 31, 2020 | 4.91 Bn |
| Sep 30, 2020 | 604.00 Mn |
| Jun 30, 2020 | 5.60 Bn |
| Mar 31, 2020 | 194.00 Mn |
| Mar 31, 2019 | 499.00 Mn |
| Dec 31, 2018 | 485.00 Mn |
| Sep 30, 2018 | 587.00 Mn |
| Jun 30, 2018 | 8.22 Bn |
| Mar 31, 2018 | 627.00 Mn |
| Dec 31, 2017 | 513.00 Mn |
| Sep 30, 2017 | 587.00 Mn |
| Jun 30, 2017 | 2.32 Bn |
| Mar 31, 2017 | 523.00 Mn |
| Dec 31, 2016 | 7.70 Bn |
| Sep 30, 2016 | 528.00 Mn |
| Jun 30, 2016 | 560.00 Mn |
| Mar 31, 2016 | 185.00 Mn |
| Dec 31, 2015 | 374.00 Mn |
| Sep 30, 2015 | 154.00 Mn |
| Mar 31, 2015 | 519.00 |
| Dec 31, 2014 | 553.00 |
| Sep 30, 2014 | 563.00 |
| Mar 31, 2014 | 675.00 |
| Sep 30, 2012 | 538.00 |
| Jun 30, 2012 | 602.00 |
| Mar 31, 2012 | 527.00 |
| Dec 31, 2011 | 999.00 |
| Sep 30, 2011 | 539.00 |
| Jun 30, 2011 | 561.00 |
| Mar 31, 2011 | 713.00 |
| Dec 31, 2010 | 504.00 |
| Sep 30, 2010 | 618.00 |
| Jun 30, 2010 | 469.00 |
| Mar 31, 2010 | 3,530.00 |
| Dec 31, 2009 | 12.14 Bn |
| Sep 30, 2009 | 2,491.00 |
| Jun 30, 2009 | 2,443.00 |
| Mar 31, 2009 | 2,296.00 |